[Myelodysplasia predominantly involving in megakaryocytic lineage successfully treated with low-dose Ara-C].
A 17 year old male was admitted because of pancytopenia. Bone marrow aspiration revealed myelodysplasia, no increase of blast cells and excessive expansion of megakaryocytic lineage. Although mild increase of bone marrow reticulin fiber was observed, no hepatosplenomegaly was recognized. Therefore he was diagnosed as refractory anemia (RA) or MDS with myelofibrosis and treated with low dose Ara-C regimen. Remission was achieved in June 1987, but the relapse occurred in Oct. 1987. His bone marrow at the relapse showed more remarkable dysplastic change than before. Sequential bone marrow examinations thereafter, revealed an increase of megakaryocytic lineage, especially immature dysplastic megakaryocytes, leading to the appearance of the abnormal megakaryoblasts (detected with anti GP IIb/IIIa antibody) as well as uncharacterized blast cells in his terminal stage. Transformation from MDS to megakaryocytic leukemia was strongly suggested. He died of severe pneumonia in March 1989. The invasion of abnormal immature megakaryocytic cells including megakaryoblasts was observed in liver, spleen and lymph nodes at autopsy. There are several reports on cases having a common hematological features such as 1) pancytopenia in peripheral blood, 2) myelodysplasia, 3) excessive growth of megakaryocytic lineage, 4) myelofibrosis without hepatosplenomegaly, although other clinical features were different. We propose all these cases should be reviewed at the point of MDS mainly involved in megakaryocytic lineage.
Tsushita
K
K
First Department of Internal Medicine, Nagoya University School of Medicine.
Hotta
T
T
Inoue
C
C
Ichikawa
A
A
Murate
T
T
Saito
H
H
D000293:Adolescent; D003561:Cytarabine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000473:pathology*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D055728:Primary Myelofibrosis / Q000473:pathology
D003561:Cytarabine